Searched for
GENERIC EPILEPSY DRUG
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Indoco Remedies gets USFDA nod to sell generic epilepsy medicineIndoco Remedies has secured approval from the US health regulator for its generic Lacosamide oral solution. This medication is used to trea...
- Zydus gets final US FDA nod to market generic version of Vigabatrin tabletsCadila Healthcare Ltd on Thursday said group firm Zydus has received final approval from the US health regulator to market its generic vers...
- Unichem Labs gets USFDA nod to market generic capsulesThe company has received abbreviated new drug application (ANDA) approval to market its Zonisamide capsules, USP 25 mg, 50 mg and 100 mg fr...
- JB Chemicals gets USFDA nod to market generic epilepsy drugJB Chemicals and Pharmaceuticals on Monday said it has received approval from the US health regulator to market Carbamazepine extended rele...
- Retail margin on generic drugs may be as high as 1,000%, claims studyPM Narendra Modi had on Monday said that government is contemplating a legislation that will make it mandatory for the doctors to prescribe...
- Jubilant Lifesciences surges as USFDA gives final nod for epilepsy drugShares of Jubilant Lifesciences surged 6 per cent in trade on Monday after the firm received final approval for its generic drug from USFDA.
- Aurobindo Pharma gets tentative nod from USFDA for Lacosamide tabletsThis ANDA is at present under litigation in the United States District Court for the District of Delaware, Aurobindo Pharma said.
- Dr Reddy's launches anti-epilepsy tablets in US marketDr Reddy's Laboratories said it has launched its generic Lamotrigine extended-release tablets, used for treating epilepsy, in the American ...
- Glenmark gets USFDA nod for anti-epileptic drugGlenmark Pharmaceuticals today said its US-based arm has received approval from the US health regulator to market generic Lamictal tablets.
- Lupin gets final US FDA nod for generic anti-epileptic drugLupin is the 5th largest generics player in the US (by prescriptions), the only Asian company to achieve that distinction.
- Sun Pharma receives USFDA nod for anti-anxiety drugSun Pharmaceutical Industries today said that it has received the US Food and Drug Administration's nod to market a generic version of alpr...
- Glenmark recalls child epilepsy drug in USGlenmark is recalling specific lots of its Oxcarbazepine tablets, used for the treatment of child epilepsy, in the US over a labelling erro...
- Sun Pharma gets US regulator's nod for epilepsy drugDrug maker Sun Pharmaceutical Industries on Thursday said it has received the US health regulator's nod for marketing a generic version of ...
- Sun Pharma gets US FDA nod to market epilepsy drugSun Pharmaceuticals says it has received US FDA approval for marketing multiple strengths of the generic version of Novartis Trileptal oxca...
- Dr Reddy's, UCB settle patent rowThis out of court settlement will enable Dr Reddy’s to launch its generic version of Keppra soon. The market size of Keppra is around one b...
- Wockhardt challenges patents litigationWockhardt Pharma has just got into the game. The co is challenging Abbott Lab patent on epilepsy drug.
Load More
